We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 05. | 장 마감 후 (AMC) | $0.08 | — | — | $46.15M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $0.37 | — | — | $48.99M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-0.02 | — | — | $147.36M |
Consensus PT $2.99 · 5 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 04. 16. | Truist Securities | — | 의견 유지 | Buy → Buy | — | Truist Securities: Buy |
| 2026. 03. 13. | B. Riley Securities | — | 의견 유지 | Neutral → Neutral | — | B. Riley Securities: Neutral |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-0.33 | — | — | $95.97M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.
Stored first · Google News · Yahoo Finance (English)
Biote names Komal Bajaj as chief medical officer - Investing.com
Biote names Komal Bajaj as chief medical officer Investing.com
Biote Appoints Dr. Komal Bajaj as Chief Medical Officer to Strengthen Clinical Quality and Care Delivery - citybiz
Biote Appoints Dr. Komal Bajaj as Chief Medical Officer to Strengthen Clinical Quality and Care Delivery citybiz
NYC hospital quality chief Komal Bajaj becomes Biote CMO - Stock Titan
NYC hospital quality chief Komal Bajaj becomes Biote CMO Stock Titan
Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer
Lilly's $1.2B deal for Hanmi GLP-2 drug for short bowel syndrome - Fierce Biotech
Lilly's $1.2B deal for Hanmi GLP-2 drug for short bowel syndrome Fierce Biotech
China’s biotech ascent forces US industry to choose: Is the country an ally or an existential threat? - The Boston Globe
China’s biotech ascent forces US industry to choose: Is the country an ally or an existential threat? The Boston Globe